Results 131 to 140 of about 33,158 (224)

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

TRIM37 interacts with PTEN to promote progression of hepatocellular carcinoma cells by modulating AKT/GSK-3β/β-Catenin pathway. [PDF]

Transl Cancer Res
Wang Q, Zhang X, Zhang J.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Selective 7‑Azaindole Modulators Targeting Fyn and GSK-3β for Dual-Target Neuromodulation. [PDF]

ACS Med Chem Lett
Shi H, Li Y, Liang SH.
europepmc   +1 more source

Neutrophil‐Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo‐Immunotherapy

Cancer Science, EarlyView.
PD‐1 blockade combined with chemotherapy induces MHC‐II+ inflammatory neutrophils in gastric cancer, which engage in dynamic crosstalk with macrophages to remodel the tumor microenvironment toward a pro‐inflammatory state, thereby amplifying antitumor immune responses.
Keita H. Nagaoka, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Takuya Nakatsuru, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Sai M. Pulukuri, Yuko Ishii, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

Moxa-combustion byproducts improve cognitive function via olfactory-mediated modulation of the GSK-3β/CREB pathway. [PDF]

Front Neurosci
Wu JW, Liu YJ, He J, Shi YQ, Zhao BX.
europepmc   +1 more source

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, EarlyView.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

Structure-activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease. [PDF]

RSC Med Chem
Rajamani G, Naqvi S, Sharma A.
europepmc   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Harnessing GSK-3β inhibition for lung cancer therapy: emerging opportunities and challenges. [PDF]

Med Oncol
Hassanein EHM, Althagafy HS, ElHafeez HHA, Ibrahim IM, Alghamdi BS.   +4 more
europepmc   +1 more source